Technical Analysis for IOBT - IO Biotech, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
MACD Bearish Signal Line Cross | Bearish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
Gapped Up | Strength | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
20 DMA Resistance | Bearish | -0.69% | |
200 DMA Resistance | Bearish | -0.69% |
Alert | Time |
---|---|
Down 5% | about 19 hours ago |
Down 3% | about 20 hours ago |
Fell Below Lower Bollinger Band | about 20 hours ago |
Fell Below Previous Day's Low | about 20 hours ago |
Lower Bollinger Band Support | about 20 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death ligand (PD-L1). It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. IO Biotech, Inc. was incorporated in 2021 and is based in Copenhagen, Denmark.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Immune System Treatment Of Cancer Cancer Therapies Anti Cancer Therapies Urea Cycle
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Immune System Treatment Of Cancer Cancer Therapies Anti Cancer Therapies Urea Cycle
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.28 |
52 Week Low | 0.8163 |
Average Volume | 93,228 |
200-Day Moving Average | 1.52 |
50-Day Moving Average | 1.58 |
20-Day Moving Average | 1.48 |
10-Day Moving Average | 1.48 |
Average True Range | 0.15 |
RSI (14) | 42.86 |
ADX | 22.09 |
+DI | 8.90 |
-DI | 17.09 |
Chandelier Exit (Long, 3 ATRs) | 1.35 |
Chandelier Exit (Short, 3 ATRs) | 1.64 |
Upper Bollinger Bands | 1.57 |
Lower Bollinger Band | 1.39 |
Percent B (%b) | 0.24 |
BandWidth | 12.10 |
MACD Line | -0.03 |
MACD Signal Line | -0.03 |
MACD Histogram | -0.0012 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.63 | ||||
Resistance 3 (R3) | 1.62 | 1.56 | 1.59 | ||
Resistance 2 (R2) | 1.56 | 1.51 | 1.56 | 1.58 | |
Resistance 1 (R1) | 1.49 | 1.48 | 1.46 | 1.50 | 1.57 |
Pivot Point | 1.43 | 1.43 | 1.41 | 1.43 | 1.43 |
Support 1 (S1) | 1.36 | 1.38 | 1.33 | 1.37 | 1.29 |
Support 2 (S2) | 1.30 | 1.35 | 1.30 | 1.28 | |
Support 3 (S3) | 1.23 | 1.30 | 1.27 | ||
Support 4 (S4) | 1.24 |